Health Dictionary Find a Doctor

Coronavirus

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2], Syed Hassan A. Kazmi BSc, MD [3], Aditya Govindavarjhulla, M.B.B.S. [4]


This is the page about a variety of coronaviruses including MERS, the original SARS virus and COVID19.

If you are interested in the page on COVID19 click here

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2] Sabawoon Mirwais, M.B.B.S, M.D.[3] Aditya Govindavarjhulla, M.B.B.S. [4]

Overview

Coronavirus is a genus of animal virus belonging to the family Coronaviridae. Coronavirus, named due to the “crown” like appearance of its surface projections, was first isolated from chickens in 1937. In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro. There are now approximately 15 species in this family, which infect not only humans but cattle, pigs, rodents, cats, dogs and birds (some are serious veterinary pathogens, especially chickens). Coronavirus gained international popularity after the deadly SARS epidemic caused by SARS-CoV in 2002 – 2003. A novel coronavirus known as the MERS-CoV was the highlight of the year 2012 when it caused the Middle East respiratory syndrome (MERS) epidemic. 2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. Based on the grouping, coronavirus can be classified into three groups. It can also be classified into families based on the genome and the method of replication. The virus can also be classified based on human infectivity. Coronavirus infection is very common and occurs worldwide. The incidence of infection is strongly seasonal, with the greatest incidence in children in winter. Adult infections are less common. The number of coronavirus serotypes and the extent of antigenic variation is unknown. Re-infections appear to occur throughout life, implying multiple serotypes (at least four are known) and/or antigenic variation, hence the prospects for immunization appear bleak. Due to the lack of data, the exact incidence rate of coronavirus infections can not be approximated. With 8,098 confirmed cases, the case fatality-rate of SARS was 9.6%. With 2465 laboratory-confirmed cases, the case fatality-rate of MERS was 34.4%. The case fatality-rate of 2019-nCoV in the first 99 patients at a Wuhan hospital (the epicenter of the outbreak) has been found to be 11%. Diagnosis of coronaviruses causing infection in humans is based on combination of clinical and epidemiological criteria. Close contact with infected individuals, travel to endemic area and detection of viral RNA in the patient’s serum are the most important criteria for confirmation of diagnosis. The history of coronavirus infection includes exposure to an infected animal or human. Patients report flu like symptoms in the initial stages. Infected people can also report upper respiratory symptoms. Common symptoms of coronavirus infection include fever, cough, and shortness of breath. The incubation period can vary depending on the infection. The mean incubation period for 2019-nCoV has been set to be 5.2 days. The pathognomonic physical examination findings in patients infected with coronavirus include fever, flu-like-symptoms, cough, and body aches. General appearance of the patient infected with coronavirus depends on the incubation period of the illness. The chest x ray findings in a suspected case of coronavirus infection can mimic the findings in pneumonia. There are no specific ECG findings associated with coronavirus infection. Non specific findings can include sinus tachycardia and diffuse T wave inversion. Chest CT scan findings in patients infected with coronavirus can include unilateral or bilateral pneumonia, mottling and ground glass opacity, focal or multifocal opacities, consolidation, and septal thickening with subpleural and lower lobe involvement more likely. Treatment should be supportive. No specific treatment available. Most people with coronavirus illness will recover on their own.

Historical Perspective

Coronaviruses were first isolated from chickens in 1937. In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro. There are now approximately 15 species in this family, which infect not only man but cattle, pigs, rodents, cats, dogs and birds (some are serious veterinary pathogens, especially chickens). Coronavirus gained international popularity after the deadly SARS epidemic caused by SARS-CoV in 2002 – 2003. A novel coronavirus known as the MERS-CoV was the highlight of the year 2012 when it caused the Middle East respiratory syndrome (MERS) epidemic. 2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.

Classification

Based on the grouping, coronavirus can be classified into three groups. It can also be classified into families based on the genome and the method of replication. The virus can also be classified based on human infectivity.

Epidemiology and Demographics

Coronaviruses have a worldwide distribution, causing 10-15% of common cold cases. Infections show a seasonal pattern with most cases occurring in the winter months. Coronavirus infection is very common and occurs worldwide. The incidence of infection is strongly seasonal, with the greatest incidence in children in winter. Adult infections are less common. The number of coronavirus serotypes and the extent of antigenic variation is unknown. Re-infections appear to occur throughout life, implying multiple serotypes (at least four are known) and/or antigenic variation, hence the prospects for immunization appear bleak. Due to the lack of data, the exact incidence rate of coronavirus infections can not be approximated. With 8,098 confirmed cases, the case fatality-rate of SARS was 9.6%. With 2465 laboratory-confirmed cases, the case fatality-rate of MERS was 34.4%. The case fatality-rate of 2019-nCoV in the first 99 patients at a Wuhan hospital (the epicenter of the outbreak) has been found to be 11%.

Risk Factors

The most significant risk factor for coronavirus infection is exposure. to infected animals or humans.

Screening

There is insufficient evidence to recommend routine screening for coronavirus infection.

Natural History, Complications and Prognosis

Coronavirus infection can have a highly variable disease course. The infection can range from being subclinical to being an overt clinical condition. Coronavirus infection is most commonly complicated by respiratory distress indicating mechanical ventilation and ICU care. The prognosis of the coronovirus infection is highly dependent on the type of the virus involved and the disease presentation. It has been noted that young children, elderly, immunocompromised, and individuals with comorbid conditions are at the highest risk for worse prognosis.

Diagnosis

Diagnostic criteria

Diagnosis of coronaviruses causing infection in humans is based on combination of clinical and epidemiological criteria. Close contact with infected individuals, travel to endemic area and detection of viral RNA in the patient’s serum are the most important criteria for confirmation of diagnosis.

History and Symptoms

The history of coronavirus infection includes exposure to an infected animal or human. Patients report flu like symptoms in the initial stages. Infected people can also report upper respiratory symptoms. Common symptoms of coronavirus infection include fever, cough, and shortness of breath. The incubation period can vary depending on the infection. The mean incubation period for 2019-nCoV has been set to be 5.2 days.

Physical Examination

The pathognomonic physical examination findings in patients infected with coronavirus include fever, flu-like-symptoms, cough, and body aches. General appearance of the patient infected with coronavirus depends on the incubation period of the illness.

Laboratory Findings

Laboratory tests can be done to confirm whether illness may be caused by human coronaviruses. However, these tests are not used very often because people usually have mild illness. Also, testing may be limited to a few specialized laboratories. Laboratory tests include serology for viral antigen, molecular testing and viral culture. All these tests can be used to confirm infection with coronavirus.

Chest X-Ray

The chest x ray findings in a suspected case of coronavirus infection can mimic the findings in pneumonia.

Electrocardiogram

There are no specific ECG findings associated with coronavirus infection. Non specific findings can include sinus tachycardia and diffuse T wave inversion.

Echocardiography and Ultrasound

There are no specific echocardiography/ultrasound findings associated with coronavirus infection. Non specific echocardiographic findings can include left ventricular systolic dysfunction and pericardial effusion.

CT Scan

Chest CT scan findings in patients infected with coronavirus can include unilateral or bilateral pneumonia, mottling and ground glass opacity, focal or multifocal opacities, consolidation, and septal thickening with subpleural and lower lobe involvement more likely.

MRI

There are no specific MRI findings associated with coronavirus infection. MRI can aide in making the diagnosis on the basis of exclusion.

Other Diagnostic Studies

Research laboratories have used isolation methods, electron microscopy, serology and PCR-based assays to diagnose coronavirus infections for surveillance studies.

Treatment

Medical Therapy

Treatment should be supportive. No specific treatment available. Most people with coronavirus illness will recover on their own.

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2], Aditya Govindavarjhulla, M.B.B.S. [3]

Overview

Coronavirus, named due to the “crown” like appearance of its surface projections, was first isolated from chickens in 1937. In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro. There are now approximately 15 species in this family, which infect not only humans but cattle, pigs, rodents, cats, dogs and birds (some are serious veterinary pathogens, especially chickens).

Historical Perspective

  • Coronavirus, named due to the “crown” like appearance of its surface projections, was first isolated from chickens in 1937.
  • In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro.
  • There are now approximately 15 species in this family, which infect not only humans but cattle, pigs, rodents, cats, dogs and birds (some are serious veterinary pathogens, especially chickens).[1]

SARS-CoV

MERS-CoV

SARS-CoV-2/COVID-19

  • 2019 Novel Coronavirus (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.[7]
  • Initially, the patients were believed to have contracted the virus from seafood/animal markets which suggested animal-to-human spread.
  • The growing number of patients however, suggest that human-to-human transmission is actively occurring.
  • In the United States, confirmed cases of COVID-19 have been reported in the states of Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Hampshire, New Jersey, New York, North Carolina, Oregon, Rhode Island, Tennessee, Texas, Washington, and Wisconsin.
  • So far, the virus has spread globally and there are confirmed cases of the disease in the following countries:
  • China, Hong Kong, Macau, Taiwan, Australia, Cambodia, Canada, Finland, France, Germany, India, Japan, Malaysia, Nepal, Philippines, Sri Lanka, Singapore, Thailand, The Republic of Korea, United Arab Emirates, United States, and Vietnam

Other Pathogenic Coronaviruses

  • The recognition of SARS led the search for other pathogenic coronaviruses, which culminated in the discovery of HCoV-NL63 and HCoV-HKU1.
  • HCoV-NL63 was isolated from hospitalized young children and HCoV-HKU1 was isolated from hospitalized elderly with comorbidities.[8][9][10]
  • HCoV-NL63, infecting humans for centuries, has been shown that it diverged from HCoV-229E approximately 1000 years ago.[11]

Evolution of the Virus

  • Genetic analyses performed at the time of the SARS epidemic showed that the virus underwent rapid adaptations in both animals and humans.[12][13]
  • The most significant of these adaptations was changing the receptor binding domain (RBD) of the S protein, allowing more efficient infection of the human cells.[14]

    References

    1. “Coronavirus – MicrobeWiki”. Retrieved 2012-12-28.
    2. Garbino J, Crespo S, Aubert JD, Rochat T, Ninet B, Deffernez C, Wunderli W, Pache JC, Soccal PM, Kaiser L (October 2006). “A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection”. Clin. Infect. Dis. 43 (8): 1009–15. doi:10.1086/507898. PMID 16983613.
    3. Peiris JS, Guan Y, Yuen KY (December 2004). “Severe acute respiratory syndrome”. Nat. Med. 10 (12 Suppl): S88–97. doi:10.1038/nm1143. PMID 15577937.
    4. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS (August 2005). “Multiple organ infection and the pathogenesis of SARS”. J. Exp. Med. 202 (3): 415–24. doi:10.1084/jem.20050828. PMC 2213088. PMID 16043521.
    5. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL (October 2003). “Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China”. Science. 302 (5643): 276–8. doi:10.1126/science.1087139. PMID 12958366.
    6. Mackay IM, Arden KE (December 2015). “MERS coronavirus: diagnostics, epidemiology and transmission”. Virol. J. 12: 222. doi:10.1186/s12985-015-0439-5. PMC 4687373. PMID 26695637.
    7. https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty |title= (help)
    8. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, Osterhaus AD (April 2004). “A previously undescribed coronavirus associated with respiratory disease in humans”. Proc. Natl. Acad. Sci. U.S.A. 101 (16): 6212–6. doi:10.1073/pnas.0400762101. PMC 395948. PMID 15073334.
    9. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Wertheim-van Dillen PM, Kaandorp J, Spaargaren J, Berkhout B (April 2004). “Identification of a new human coronavirus”. Nat. Med. 10 (4): 368–73. doi:10.1038/nm1024. PMID 15034574.
    10. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, Wong BH, Poon RW, Cai JJ, Luk WK, Poon LL, Wong SS, Guan Y, Peiris JS, Yuen KY (January 2005). “Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia”. J. Virol. 79 (2): 884–95. doi:10.1128/JVI.79.2.884-895.2005. PMC 538593. PMID 15613317.
    11. Pyrc K, Dijkman R, Deng L, Jebbink MF, Ross HA, Berkhout B, van der Hoek L (December 2006). “Mosaic structure of human coronavirus NL63, one thousand years of evolution”. J. Mol. Biol. 364 (5): 964–73. doi:10.1016/j.jmb.2006.09.074. PMID 17054987.
    12. “Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China”. Science. 303 (5664): 1666–9. March 2004. doi:10.1126/science.1092002. PMID 14752165.
    13. Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, Chen QX, Gao YW, Zhou HQ, Xiang H, Zheng HJ, Chern SW, Cheng F, Pan CM, Xuan H, Chen SJ, Luo HM, Zhou DH, Liu YF, He JF, Qin PZ, Li LH, Ren YQ, Liang WJ, Yu YD, Anderson L, Wang M, Xu RH, Wu XW, Zheng HY, Chen JD, Liang G, Gao Y, Liao M, Fang L, Jiang LY, Li H, Chen F, Di B, He LJ, Lin JY, Tong S, Kong X, Du L, Hao P, Tang H, Bernini A, Yu XJ, Spiga O, Guo ZM, Pan HY, He WZ, Manuguerra JC, Fontanet A, Danchin A, Niccolai N, Li YX, Wu CI, Zhao GP (February 2005). “Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human”. Proc. Natl. Acad. Sci. U.S.A. 102 (7): 2430–5. doi:10.1073/pnas.0409608102. PMC 548959. PMID 15695582.
    14. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M (April 2005). “Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2”. EMBO J. 24 (8): 1634–43. doi:10.1038/sj.emboj.7600640. PMC 1142572. PMID 15791205.

    Template:WH Template:WS

    Classification

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Sabawoon Mirwais, M.B.B.S, M.D.[3]

    Overview

    Based on the grouping, coronavirus can be classified into three groups. It can also be classified into families based on the genome and the method of replication. The virus can also be classified based on human infectivity.

    Classification

    Based on Groups

    Genus Coronavirus

    Based on Baltimore Classification

    The Baltimore classification, developed by David Baltimore, is a virus classification system that groups viruses into families, depending on their type of genome (DNA, RNA, single-stranded (ss), double-stranded (ds), etc.) and their method of replication.[3]

    • Virus
    • ssRNA positive-strand viruses
    • No DNA stage
    • Nidovirales
    • Coronaviridae
    • Coronavirus

    Human Coronaviruses

    References

    1. Woo PC, Lau SK, Chu CM; et al. (2005). “Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia”. J Virol. 79: 884&ndash, 95. doi:10.1128/JVI.79.2.884-895.2005.
    2. Vabret A, Dina J, Gouarin S; et al. (2006). “Detection of the new human coronavirus HKU1: a report of 6 cases”. Clin Infect Dis. 42: 634&ndash, 9. doi:10.1086/500136.
    3. “Coronavirus – MicrobeWiki”. Retrieved 2012-12-28.

    Template:WH Template:WS

    Pathophysiology

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

    Pathophysiology

    Structure

    Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetry. The genomic size of coronaviruses ranges from approximately 16 to 31 kilobases, extraordinarily large for an RNA virus. The name coronavirus is derived from the greek (κορώνα, meaning crown) as the virus envelope appears under electron microscopy (E.M.) to be crowned by a characteristic ring of small bulbous structures. This morphology is actually formed by the viral spike (S) peplomers, which are proteins that populate the surface of the virus and determine host tropism. Coronaviruses are grouped in the order Nidovirales, named for the Latin (nidus, meaning nest) as all viruses in this order produce a 3′ co-terminal nested set of subgenomic mRNA’s during infection.

    Proteins that contribute to the overall structure of all coronaviruses are the spike (S), envelope (E), membrane (M) and nucleocapsid (N). In the specific case of SARS, a defined receptor-binding domain on S mediates the attachment of the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2).[1] Members of the group 2 coronaviruses also have a shorter spike-like protein called hemagglutinin esterase (HE) encoded in their genome, but for some reason this protein is not always brought to expression (produced) in the cell.[2]

    Structure of Coronavirus


    Replication of Coronaviruses

    The infection cycle of coronavirus


    Replication of Coronavirus begins with entry to the cell takes place in the cytoplasm in a membrane-protected microenvironment, upon entry to the cell the virus particle is uncoated and the RNA genome is deposited into the cytoplasm. The Coronavirus genome has a 5’ methylated cap and a 3’polyadenylated-A tail to make it look as much like the host RNA as possible. This also allows the RNA to attach to ribosomes for translation. Coronaviruses also have a protein known as a replicase encoded in its genome which allows the RNA viral genome to be translated into RNA by using the host cells machinery. The replicase is the first protein to be made as once the gene encoding the replicase is translated the translation is stopped by a stop codon. This is known as a nested transcript, where the transcript only encodes one gene- it is monocistronic. The RNA genome is replicated and a long polyprotein is formed, where all of the proteins are attached. Coronaviruses have a non-structural protein called a protease which is able to separate the proteins in the chain. This is a form of genetic economy for the virus allowing it to encode the most amounts of genes in a small amount of nucleotides.

    Coronavirus transcription involves a discontinuous RNA synthesis (template switch) during the extension of a negative copy of the subgenomic mRNAs. Base pairing during transcription is a requirement. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Both viral and cellular proteins are required for replication and transcription. Coronaviruses initiate translation by cap-dependent and cap-independent mechanisms. Cell macromolecular synthesis may be controlled after Coronavirus infection by locating some virus proteins in the host cell nucleus. Infection by different coronaviruses cause in the host alteration in the transcription and translation patterns, in the cell cycle, the cytoskeleton, apoptosis and coagulation pathways, inflammation, and immune and stress responses.[3]

    Transmission

    They are transmitted by aerosols of respiratory secretions, by the fecal-oral route, and by mechanical transmission. Most virus growth occurs in epithelial cells. Occasionally the liver, kidneys, heart or eyes may be infected, as well as other cell types such as macrophages. In cold-type respiratory infections, growth appears to be localized to the epithelium of the upper respiratory tract, but there is no adequate animal model for the human respiratory coronaviruses.

    • Incubation period: 2 – 4 days.
    • Communicability: Human-to-human transmission is possible during the presence of infectious droplets, which can cause infection via inhalation, or through contaminated surfaces.
    • Dissemination
      • Reservoir: Humans.
      • Vectors: None.
      • Dissemination: None.

    Role of Spike Proteins

    • They induce neutralizing antibody.
    • They are important in relating host cell tropism.
    • Hemagglutination.
    • They mediate the cell to cell or cell to viral fusion by the interaction between viral envelope and the specific receptor of host cell membrane.

    Pathogenicity

    Coronaviruses primarily infect the upper respiratory and gastrointestinal tract of mammals and birds. Four to five different currently known strains of coronaviruses infect humans. The most publicized human coronavirus, SARS-CoV which causes SARS, has a unique pathogenesis because it causes both upper and lower respiratory tract infections and can also cause gastroenteritis. Coronaviruses are believed to cause a significant percentage of all common colds in human adults. Coronaviruses cause colds in humans primarily in the winter and early spring seasons. The significance and economic impact of coronaviruses as causative agents of the common cold are hard to assess because, unlike rhinoviruses (another common cold virus), human coronaviruses are difficult to grow in the laboratory.

    These viruses infect a variety of mammals and birds. The exact number of human isolates are not known as many cannot be grown in culture. In humans, they cause:

    • Respiratory infections (common), including Severe Acute Respiratory Syndrome (SARS).
    • Enteric infections (occasional – mostly in infants <12 months).
    • Neurological syndromes (rare).

    Coronaviruses also cause a range of diseases in farm animals and domesticated pets, some of which can be serious and are a threat to the farming industry. Economically significant coronaviruses of farm animals include porcine coronavirus (transmissible gastroenteritis, TGE) and bovine coronavirus, which both result in diarrhea in young animals. Feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality. There are two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MHV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice. Prior to the discovery of SARS-CoV, MHV had been the best studied coronavirus both in vivo and in vitro as well as at the molecular level. Some strains of MHV cause a progressive demyelinating encephalitis in mice which has been used as a murine model for multiple sclerosis. Significant research efforts have been focused on elucidating the viral pathogenesis of these animal coronaviruses, especially by virologists interested in veterinary and zoonotic diseases.

    HCoV-229E and HCoV-OC43 cause the common cold, a self-limiting upper respiratory tract infection. Infection can lead to a number of illnesses such as bronchitis, gastroenteritis, progressive demyelinating encephalitis, diarrhea, peritonitis, nasal obstruction, rhinorrhea, sneezing, sore throat and cough. They can cause more severe lower respiratory tract infection, including pneumonia in infants, elderly and immunocompromised individuals.

    HCoV-229E is a common agent if coryza, whereas HCoV-OC43 is generally characterized by sore throats.

    HCoV-NL63 causes laryngotracheitis (croup) and nonfatal upper and lower respiratory tract infections in children, elderly, and immunocompromised individuals. HCoV-HKU1 causes mild upper respiratory diseases, the common cold, bronchiolitis, and pneumonia, with symptoms such as rhinorrhea, fever, cough, febrile seizure, and wheezing. More severe illness may occur in children, adults with underlying disease, the elderly, and may be associated with gastrointestinal illness.

    Laboratory Hazards

    No infections have been reported. However, this may be an underestimate of the number of incidences as symptoms are nonspecific and self limiting.

    Stablity and Viability

    • Drug Susceptibility: Currently, there are no specific antiviral drugs for coronavirus available.[4]
    • Susceptibility to Disinfectants: Susceptible to 0.1% sodium hypochlorite, 0.1% organochlorine, 10% iodophore, 70% ethanol and 2% glutaraldehyde. Resistant to 0.04% quaternary ammonium compound and phenolics.
    • Physical Inactivation: Inactivation by UV light can be done by exposure to 1200 µJ/cm2 for 30 minutes.
    • Survival Outside Host: Survives up to six days in aqueous mediums and up to 3 hours on dry inanimate surfaces.

    Associated Conditions

    Conditions associated with coronavirus infection may include:

    References

    1. Li, Fang, et. al. (2005). “Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor”. Science. 309: 1864&ndash, 1868. doi:10.1126/science.1116480.
    2. de Haan CAM, Rottier PJM (2005). “Molecular Interactions in the Assembly of Coronaviruses”. Advances in Virus Research. 64: 185&ndash, 186.
    3. Enjuanes; et al. (2008). “Coronavirus Replication and Interaction with Host”. Animal Viruses: Molecular Biology. Caister Academic Press. ISBN 978-1-904455-22-6.
    4. “Human Coronavirus – Pathogen Safety Data Sheets”. Retrieved 2012-12-28.
    5. https://www.cdc.gov/coronavirus/mers/about/symptoms.html. Missing or empty |title= (help)
    6. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, Saeed BT, Wahbi A, Saedy A, AlDabbagh T, Okaili R, Sadat M, Balkhy H (August 2015). “Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)”. Infection. 43 (4): 495–501. doi:10.1007/s15010-015-0720-y. PMC 4521086. PMID 25600929.

    Template:WH Template:WS

    Differentiating Coronavirus from other Diseases

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2] Syed Hassan A. Kazmi BSc, MD [3]

    Overview

    Coronavirus infection should be differentiated from other diseases presenting with cough, fever, shortness of breath and tachypnea.

    Differentiating Coronavirus Infection from other Diseases

    Coronavirus infection should be differentiated from other diseases presenting with cough, fever, shortness of breath and tachypnea. The differentials include the following:[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]

    Diseases Diagnostic tests Physical Examination Symptoms Past medical history Other Findings
    CT scan and MRI EKG Chest X-ray Tachypnea Tachycardia Fever Chest Pain Hemoptysis Dyspnea on Exertion Wheezing Chest Tenderness Nasalopharyngeal Ulceration Carotid Bruit
    COVID-19
    • Consolidation
    • Peripheral ground glass opacity
    ✔/- ✔/-
    • Possible exposure to infected animals or persons
    Pulmonary embolism
    • On CT angiography:
      • Intra-luminal filling defect
    • On MRI:
      • Narrowing of involved vessel
      • No contrast seen distal to obstruction
      • Polo-mint sign (partial filling defect surrounded by contrast)
    ✔ (Low grade) ✔ (In case of massive PE)
    Congestive heart failure
    • Goldberg’s criteria may aid in diagnosis of left ventricular dysfunction: (High specificity)
      • SV1 or SV2 + RV5 or RV6 ≥3.5 mV
      • Total QRS amplitude in each of the limb leads ≤0.8 mV
      • R/S ratio <1 in lead V4
    Percarditis
    • ST elevation
    • PR depression
    • Large collection of fluid inside the pericardial sac (pericardial effusion)
    • Calcification of pericardial sac
    ✔ (Low grade) ✔ (Relieved by sitting up and leaning forward)
    • May be clinically classified into:
      • Acute (< 6 weeks)
      • Sub-acute (6 weeks – 6 months)
      • Chronic (> 6 months)
    Pneumonia
    Vasculitis

    Homogeneous, circumferential vessel wall swelling

    Chronic obstructive pulmonary disease (COPD)
    • On CT scan:
    • On MRI:
      • Increased diameter of pulmonary arteries
      • Peripheral pulmonary vasculature attentuation
      • Loss of retrosternal airspace due to right ventricular enlargement
      • Hyperpolarized Helium MRI may show progressively poor ventilation and destruction of lung


    Differentiating 2019-nCoV, MERS-CoV and SARS-CoV




    Type of Coronavirus Origins Family (Lineage) Receptor Incubation Period Genome size Clinical Features Transmission Epidemiology Cytokine Profile Imaging Findings Serological Testing
    Fever Dry cough Dyspnea Rhinorrhea Sneezing Sore throat Diarrhea
    2019-nCoV
    • Huanan seafood market, Wuhan, Hubei China (December 2019)
    • Betacoronaviridea, subgenus: Sarbecovirus (Lineage B)
    • ACE1/2
    • 1-14 days
    • 29.8 kB (> 80% nucleotide identity with SARS-CoV)
    ++ ++ ++ + + +
    • Human to human transmission through close contact
    • 14380 confirmed cases
    • 17 deaths
    • Males > females
    • Mortality rate 2.7%
    • IL1B, IFNγ, IP10, and MCP1
    • GCSF, IP10, MCP1, MIP1A, and TNFα (ICU-admitted)
    • IL4 and IL10
    • On CT scan:
      • Bilateral ground-glass opacities
      • Peripheral localization and subpleural sparing
    MERS-CoV
    • Saudi Arabia (September 2012)
    • Betacoronaviridea (Lineage C)
    • DPP4 (CD26)
    • 2-14 days
    • 29.9 kB
    ++ ++ ++ ++ ++ ++ +
    • Limited human to human trasnmission
    • Reservoirs:
      • Bats
      • Civets
      • Camels
    • 2494 confirmed cases
    • 858 deaths
    • Mortality rate of 34%
    • IFNγ, TNFα, IL15, and IL17
    • On CT scan:
      • Bilateral, subpleural and basilar infiltrates
      • Ground glass opacities
      • Organizing pneumonia-like pattern (subpleural and peribroncho-vascular)
    SARS-CoV
    • Guangdong, Southern China (November 2002)
    • Betacoronaviridea (Lineage B)
    • ACE2
    • 2-7 days
    • 29.3 kB
    ++ ++ ++ ++ ++ ++ +
    • Human to human transmission through close contact
    • Reservoirs:
      • Bats
      • Civets
      • Camels
    • 8098 cases
    • 774 deaths
    • Mortality rate of about 10%
    • IL1B, IL6, IL12, IFNγ, IP10, and MCP1
    • On CT scan:
      • Airspace consolidation
      • Focal or multi-focal opacities

    References

    1. Brenes-Salazar JA (2014). “Westermark’s and Palla’s signs in acute and chronic pulmonary embolism: Still valid in the current computed tomography era”. J Emerg Trauma Shock. 7 (1): 57–8. doi:10.4103/0974-2700.125645. PMC 3912657. PMID 24550636.
    2. “CT Angiography of Pulmonary Embolism: Diagnostic Criteria and Causes of Misdiagnosis | RadioGraphics”.
    3. Bĕlohlávek J, Dytrych V, Linhart A (2013). “Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism”. Exp Clin Cardiol. 18 (2): 129–38. PMC 3718593. PMID 23940438.
    4. “Pulmonary Embolism: Symptoms – National Library of Medicine – PubMed Health”.
    5. Ramani GV, Uber PA, Mehra MR (2010). “Chronic heart failure: contemporary diagnosis and management”. Mayo Clin. Proc. 85 (2): 180–95. doi:10.4065/mcp.2009.0494. PMC 2813829. PMID 20118395.
    6. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL (2008). “Symptom distress and quality of life in patients with advanced congestive heart failure”. J Pain Symptom Manage. 35 (6): 594–603. doi:10.1016/j.jpainsymman.2007.06.007. PMC 2662445. PMID 18215495.
    7. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ (2009). “Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology”. Eur. J. Heart Fail. 11 (2): 130–9. doi:10.1093/eurjhf/hfn013. PMC 2639415. PMID 19168510.
    8. Takasugi JE, Godwin JD (1998). “Radiology of chronic obstructive pulmonary disease”. Radiol. Clin. North Am. 36 (1): 29–55. PMID 9465867.
    9. Wedzicha JA, Donaldson GC (2003). “Exacerbations of chronic obstructive pulmonary disease”. Respir Care. 48 (12): 1204–13, discussion 1213–5. PMID 14651761.
    10. Nakawah MO, Hawkins C, Barbandi F (2013). “Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome”. J Am Board Fam Med. 26 (4): 470–7. doi:10.3122/jabfm.2013.04.120256. PMID 23833163.
    11. Khandaker MH, Espinosa RE, Nishimura RA, Sinak LJ, Hayes SN, Melduni RM, Oh JK (2010). “Pericardial disease: diagnosis and management”. Mayo Clin. Proc. 85 (6): 572–93. doi:10.4065/mcp.2010.0046. PMC 2878263. PMID 20511488.
    12. Bogaert J, Francone M (2013). “Pericardial disease: value of CT and MR imaging”. Radiology. 267 (2): 340–56. doi:10.1148/radiol.13121059. PMID 23610095.
    13. Gharib AM, Stern EJ (2001). “Radiology of pneumonia”. Med. Clin. North Am. 85 (6): 1461–91, x. PMID 11680112.
    14. Schmidt WA (2013). “Imaging in vasculitis”. Best Pract Res Clin Rheumatol. 27 (1): 107–18. doi:10.1016/j.berh.2013.01.001. PMID 23507061.
    15. Suresh E (2006). “Diagnostic approach to patients with suspected vasculitis”. Postgrad Med J. 82 (970): 483–8. doi:10.1136/pgmj.2005.042648. PMC 2585712. PMID 16891436.
    16. Stein PD, Dalen JE, McIntyre KM, Sasahara AA, Wenger NK, Willis PW (1975). “The electrocardiogram in acute pulmonary embolism”. Prog Cardiovasc Dis. 17 (4): 247–57. PMID 123074.
    17. Warnier MJ, Rutten FH, Numans ME, Kors JA, Tan HL, de Boer A, Hoes AW, De Bruin ML (2013). “Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease”. COPD. 10 (1): 62–71. doi:10.3109/15412555.2012.727918. PMID 23413894.
    18. Stein PD, Matta F, Ekkah M, Saleh T, Janjua M, Patel YR, Khadra H (2012). “Electrocardiogram in pneumonia”. Am. J. Cardiol. 110 (12): 1836–40. doi:10.1016/j.amjcard.2012.08.019. PMID 23000104.
    19. Hazebroek MR, Kemna MJ, Schalla S, Sanders-van Wijk S, Gerretsen SC, Dennert R, Merken J, Kuznetsova T, Staessen JA, Brunner-La Rocca HP, van Paassen P, Cohen Tervaert JW, Heymans S (2015). “Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis”. Int. J. Cardiol. 199: 170–9. doi:10.1016/j.ijcard.2015.06.087. PMID 26209947.
    20. Dennert RM, van Paassen P, Schalla S, Kuznetsova T, Alzand BS, Staessen JA, Velthuis S, Crijns HJ, Tervaert JW, Heymans S (2010). “Cardiac involvement in Churg-Strauss syndrome”. Arthritis Rheum. 62 (2): 627–34. doi:10.1002/art.27263. PMID 20112390.
    21. https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html. Missing or empty |title= (help)
    22. Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
    23. Chan, Jasper Fuk-Woo; Kok, Kin-Hang; Zhu, Zheng; Chu, Hin; To, Kelvin Kai-Wang; Yuan, Shuofeng; Yuen, Kwok-Yung (2020). “Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emerging Microbes & Infections. 9 (1): 221–236. doi:10.1080/22221751.2020.1719902. ISSN 2222-1751.
    24. Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J; Wang, Dayan; Xu, Wenbo; Holmes, Edward C; Gao, George F; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie (2020). “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. The Lancet. doi:10.1016/S0140-6736(20)30251-8. ISSN 0140-6736.
    25. Ajlan, Amr M.; Ahyad, Rayan A.; Jamjoom, Lamia Ghazi; Alharthy, Ahmed; Madani, Tariq A. (2014). “Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: Chest CT Findings”. American Journal of Roentgenology. 203 (4): 782–787. doi:10.2214/AJR.14.13021. ISSN 0361-803X.
    26. Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
    27. “Coronavirus | Home | CDC”.
    28. Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA (August 2018). “Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics”. Eur Rev Med Pharmacol Sci. 22 (15): 4956–4961. doi:10.26355/eurrev_201808_15635. PMID 30070331.
    29. Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Jiang S (December 2014). “Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein”. Virus Res. 194: 200–10. doi:10.1016/j.virusres.2014.10.007. PMID 25451066.
    30. Hajjar SA, Memish ZA, McIntosh K (2013). “Middle East Respiratory Syndrome Coronavirus (MERS-CoV): a perpetual challenge”. Ann Saudi Med. 33 (5): 427–36. doi:10.5144/0256-4947.2013.427. PMC 6074883. PMID 24188935.
    31. Memish ZA, Assiri AM, Al-Tawfiq JA (December 2014). “Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications”. Int. J. Infect. Dis. 29: 307–8. doi:10.1016/j.ijid.2014.10.002. PMID 25448335.
    32. Satija N, Lal SK (April 2007). “The molecular biology of SARS coronavirus”. Ann. N. Y. Acad. Sci. 1102: 26–38. doi:10.1196/annals.1408.002. PMID 17470909.
    33. Bolles M, Donaldson E, Baric R (December 2011). “SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission”. Curr Opin Virol. 1 (6): 624–34. doi:10.1016/j.coviro.2011.10.012. PMC 3237677. PMID 22180768.
    34. Fehr AR, Perlman S (2015). “Coronaviruses: an overview of their replication and pathogenesis”. Methods Mol. Biol. 1282: 1–23. doi:10.1007/978-1-4939-2438-7_1. PMC 4369385. PMID 25720466.

    Template:WH Template:WS

    Epidemiology and Demographics

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2], Syed Hassan A. Kazmi BSc, MD [3]

    Overview

    Due to the lack of data, the exact incidence rate of coronavirus infections can not be approximated. With 8,098 confirmed cases, the case fatality-rate of SARS was 9.6%. With 2465 laboratory-confirmed cases, the case fatality-rate of MERS was 34.4%. The case fatality-rate of SARS-CoV-2 in the first 99 patients at a Wuhan hospital (the epicenter of the outbreak) has been found to be 11%.

    Epidemiology and Demographics

    Incidence

    Prevalance

    • From June 2012 to April 2018, MERS-CoV infection was prevalent in 2206 people globally.
    • To date, 100,330 confirmed cases of COVID-19 have emerged.
    • For details on the real-time prevalence and spread of COVID-19, click here.[1]

    Case-fatality rate

    Age

    Race

    Gender

    Region

    • Majority of the cases of SARS-CoV infection were reported in China before spreading to 29 other countries.[9]
    • Majority of the cases of MERS-CoV infection were reported in the Middle East (mainly in the Kingdom of Saudi Arabia) before spreading to 27 other countries.
    • Majority of the cases of COVID-19 have been reported in China and the disease has spread to 67 countries (including the United States) so far.[10]
      • For more real-time details regarding the spread of COVID-19, click here.[11]

    Recent Outbreaks

    SARS-CoV-2

    Global

    • Majority of the cases of COVID-19 have been reported in China and the disease has spread to 67 countries (including the United States) so far.[10]
    Globally confirmed cases of COVID-19[12]


    Status in the United States

    Total Cases 43
    Total hospitalized 17
    Total deaths 2
    States reporting cases 10
    • These data represent cases detected and tested in the United States through U.S. public health surveillance systems since January 21, 2020. It does not include people who returned to the U.S. via State Department-chartered flights.[13]
    • For details on the real-time prevalence and spread of COVID-19 in the United States, click here.


    References

    1. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Missing or empty |title= (help)
    2. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E (January 2020). “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China”. Int. J. Infect. Dis. 91: 264–266. doi:10.1016/j.ijid.2020.01.009. PMID 31953166.
    3. Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
    4. Wang, Dawei; Hu, Bo; Hu, Chang; Zhu, Fangfang; Liu, Xing; Zhang, Jing; Wang, Binbin; Xiang, Hui; Cheng, Zhenshun; Xiong, Yong; Zhao, Yan; Li, Yirong; Wang, Xinghuan; Peng, Zhiyong (2020). “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China”. JAMA. doi:10.1001/jama.2020.1585. ISSN 0098-7484.
    5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (February 2020). “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. PMID 31986264.
    6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (February 2020). “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. PMID 32007143 Check |pmid= value (help).
    7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (February 2020). “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. JAMA. doi:10.1001/jama.2020.1585. PMID 32031570 Check |pmid= value (help).
    8. Li, Qun; Guan, Xuhua; Wu, Peng; Wang, Xiaoye; Zhou, Lei; Tong, Yeqing; Ren, Ruiqi; Leung, Kathy S.M.; Lau, Eric H.Y.; Wong, Jessica Y.; Xing, Xuesen; Xiang, Nijuan; Wu, Yang; Li, Chao; Chen, Qi; Li, Dan; Liu, Tian; Zhao, Jing; Liu, Man; Tu, Wenxiao; Chen, Chuding; Jin, Lianmei; Yang, Rui; Wang, Qi; Zhou, Suhua; Wang, Rui; Liu, Hui; Luo, Yinbo; Liu, Yuan; Shao, Ge; Li, Huan; Tao, Zhongfa; Yang, Yang; Deng, Zhiqiang; Liu, Boxi; Ma, Zhitao; Zhang, Yanping; Shi, Guoqing; Lam, Tommy T.Y.; Wu, Joseph T.; Gao, George F.; Cowling, Benjamin J.; Yang, Bo; Leung, Gabriel M.; Feng, Zijian (2020). “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia”. New England Journal of Medicine. doi:10.1056/NEJMoa2001316. ISSN 0028-4793.
    9. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E (January 2020). “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China”. Int. J. Infect. Dis. 91: 264–266. doi:10.1016/j.ijid.2020.01.009. PMID 31953166.
    10. 10.0 10.1 https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html. Missing or empty |title= (help)
    11. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Missing or empty |title= (help)
    12. https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html. Missing or empty |title= (help)
    13. https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html. Missing or empty |title= (help)

    Template:WH Template:WS

    Risk Factors

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

    Overview

    The most significant risk factor for coronavirus infection is exposure to infected animals and humans.

    Risk Factors

    References

    Template:WH Template:WS

    Screening

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

    Overview

    There is insufficient evidence to recommend routine screening for coronavirus infection.

    Screening

    • There is insufficient evidence to recommend routine screening for coronavirus infection.
    • In the wake of the recent SARS-CoV-2 outbreak, people with a recent travel history of China and Southeast Asia are actively being screened and evaluated at the ports of entry.
      • The evaluation is majorly dependent on travelers’ history of travel and the presence/absence of symptoms.

    References

    Template:WH Template:WS

    Natural History, Complications and Prognosis

    Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

    Overview

    Coronavirus infection can have a highly variable disease course. The infection can range from being subclinical to being an overt clinical condition. Coronavirus infection is most commonly complicated by respiratory distress indicating mechanical ventilation and ICU care. The prognosis of the coronovirus infection is highly dependent on the type of the virus involved and the disease presentation. It has been noted that young children, elderly, immunocompromised, and individuals with comorbid conditions are at the highest risk for worse prognosis.

    Natural History, Complications, and Prognosis

    Natural History

    SARS
    MERS

    COVID-19

    Complications

    Prognosis

    References

    1. (PDF) https://www.cdc.gov/sars/about/fs-SARS.pdf. Missing or empty |title= (help)
    2. https://www.cdc.gov/coronavirus/mers/about/symptoms.html. Missing or empty |title= (help)
    3. https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html. Missing or empty |title= (help)
    4. Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
    5. Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
    6. https://www.cdc.gov/coronavirus/mers/about/symptoms.html. Missing or empty |title= (help)
    7. Chen, Nanshan; Zhou, Min; Dong, Xuan; Qu, Jieming; Gong, Fengyun; Han, Yang; Qiu, Yang; Wang, Jingli; Liu, Ying; Wei, Yuan; Xia, Jia’an; Yu, Ting; Zhang, Xinxin; Zhang, Li (2020). “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. The Lancet. doi:10.1016/S0140-6736(20)30211-7. ISSN 0140-6736.
    8. Alhogbani T (2016). “Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus”. Ann Saudi Med. 36 (1): 78–80. doi:10.5144/0256-4947.2016.78. PMC 6074274. PMID 26922692.
    9. Das KM, Lee EY, Al Jawder SE, Enani MA, Singh R, Skakni L, Al-Nakshabandi N, AlDossari K, Larsson SG (September 2015). “Acute Middle East Respiratory Syndrome Coronavirus: Temporal Lung Changes Observed on the Chest Radiographs of 55 Patients”. AJR Am J Roentgenol. 205 (3): W267–74. doi:10.2214/AJR.15.14445. PMID 26102309.

    Template:WH Template:WS

    Diagnosis

    Diagnosis

    History and Symptoms | Physical Examination | Laboratory Findings | X-ray | Electrocardiogram | Echocardiography and Ultrasound | CT scan | MRI | Other Imaging Findings | Other Diagnostic Studies

    Treatment

    Treatment

    Medical Therapy | Surgery | Primary Prevention | Secondary Prevention

    Case Studies

    Case Studies

    Case #1

    Related Chapters
    External Links

    Template:Common Cold

    da:Coronavirus de:Coronaviren it:Coronavirus nl:Coronavirussen

    Template:WH Template:WS

    Looking for the patient version?

    Back to the patient-friendly article

    © 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH